Trial 3C-20-6


An open-label, multicenter, randomized phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic BRAFV600E-mutant colorectal cancer

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Local
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Fahim Raian, D.M., Victoria Amran, Coordinator, Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Angela Smith Bryant, Coordinator, Eva Ritzmann, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.